Irritable bowel syndrome (IBS) is among the most common disorders gastroenterol-ogists and primary care physicians encounter. In the past 10 years, research strides have radically changed how patients with IBS are diagnosed and treated.
Late last year the American College of Gastroenterology Functional Gastrointestinal Disorders Task Force developed a consensus document, An Evidence-Based Position Statement and Systematic Review on the Management of IBS in North America, which was published as a supplement to the American Journal of Gastroenterology. The aim of this document is to equip physicians with practical resources they can use to diagnose, treat, and manage IBS patients in their clinical practices.
The task force gave the highest recommendations (based on supporting evidence and quality of clinical trials) to the only 2 approved treatments for the multiple symptoms of IBS:
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs